skip to Main Content

LegWorks developing better, more affordable prosthetic knees for developing world

TORONTO (May 27, 2015)  – LegWorks Inc., backed with a $2 million blend of private and Government of Canada investments catalyzed by Grand Challenges Canada, is a new Toronto-based company that will contribute to a better life for amputees in developing countries.

The LegWorks AT-knee was covered in the Toronto Star on June 1, 2015 in “Great advances being made in assistive technology” by Kate Allen and in Healio Orthotics & Prosthetics News on June 2.

LegWorks3
Stripping the ability to walk, lower-limb amputation restricts independence, employment potential and productive participation in the community and affects over 10 million people. The WHO estimates that only five to 15 per cent of all lower-limb amputees in the developing world have access to appropriate prosthetic services and technologies — a large unmet need. Photo credit: Patrick Brown © 2014 Panos.

The LegWorks “All-Terrain Knee” (AT-Knee) is a safe, high-functioning, durable, affordable prosthetic knee joint developed at Toronto’s Holland Bloorview Kids Rehabilitation Hospital.  It enables lower-limb amputees to walk more efficiently, safely and comfortably.  Its patented design provides incredible stability, is easy to fit and maintain, and can even be used in harsh environments, including water.

“With the AT-Knee and LegWorks, it is our goal to begin to provide more universal access to better prosthetic care for individuals living with amputations around the world,” said Jan Andrysek, scientist in the Bloorview Research Institute at Holland Bloorview Kids Rehabilitation Hospital. “We want to make high-quality and well-functioning prosthetic devices affordable and accessible for the many individuals whose needs are currently left unmet.”

In trials, early users in 10 countries reported a 95 per cent preference for the relatively low-cost AT-Knee to more expensive existing technologies. Developed with a $100,000 Grand Challenges Canada seed grant awarded in 2012 to the Bloorview Research Institute, the AT-Knee easily outperformed existing technologies under rigorous conditions in El Salvador, Chile and Myanmar.

LegWorks LogoWith the new funding, LegWorks will mass produce its innovative, affordable prosthetic knee, the All-Terrain Knee (AT-Knee), the functionality and durability of which makes it ideal for amputees living in the developing world. The $2 million investment deal includes a loan via Grand Challenges Canada of up to $1 million (of which $405,000 has been dispersed), matched by MaRS Innovation, Holland Bloorview Kids Rehabilitation Hospital, Ontario Centres of Excellence and a group of private angel investors. With the $1 million expected from private investors and foundations matched by federal funds, the project will receive an anticipated $2 million to scale-up the success of the company.

In the first five years, LegWorks expects 37,000 units to be sold via distributors, NGOs, prosthetic clinics and government rehab facilities, in both high-income countries and the developing world.

Continue Reading

Triphase signs collaboration and option agreement with Celgene Corporation, leading innovator of cancer therapies

MI portfolio company actively seeking additional products for licensing and development

Triphase-logo-WebTORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator.

Triphase Accelerator’s announcement was covered in Yonge Street Media, Bloomburg Businessweek and Global University Venturing.

Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the time and expense between an investigational new drug application and “proof-of-concept” at Phase II.

Triphase, spun out of the Ontario Institute for Cancer Research (OICR), develops and advances late pre-clinical, Phase I or early Phase II potential products. Triphase and its founding investors are in a position to take advantage of the excellent research and development capabilities in the Toronto healthcare and innovation ecosystem.

The Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation Ventures Trust, and MaRS Phase II Investment Trust, are all Toronto-based equity investors in Triphase.

After company formation, Triphase entered into a strategic relationship with Celgene Corporation. Through this arrangement, Celgene obtained rights of first refusal on the first three oncology products Triphase advances to clinical proof-of-concept (POC), plus a right of first negotiation on three more future oncology products which may be acquired by Triphase.

Continue Reading

Crowdmark to save teacher marking time and government dollars

Ed-tech start-up completes successful EQAO and Canadian Open Math Challenge pilots

Crowdmark Logo: Grade BetterTORONTO, Canada (June 11, 2013) — Crowdmark Inc., a Canadian education technology start-up, is positioned to save cash-strapped Departments of Education millions by making massive-scale testing more efficient. Crowdmark has raised $600,000 in seed funding through the University of Toronto Early-Stage Technology (UTEST) program, MaRS Innovation and U of T’s Connaught Fund, among others.

This story was covered by Yonge Street Media, TechVibes, EdSurge and PEHub.

Dr. James Colliander, co-founder and CEO of Crowdmark
Dr. James Colliander, co-founder and CEO of Crowdmark.

The Crowdmark assessment interface, informed by decades of teaching experience and research by company co-founders, James Colliander (Professor of Mathematics) and Martin Muñoz (Researcher and Developer), at the University of Toronto, streamlines the complicated and time-consuming grading workflow for teachers.

Crowdmark archives student work and all grading feedback into individual digital portfolios that students and parents may access any time online and via mobile devices.

Through two separate pilot projects, Crowdmark has achieved proof-of-concept as a novel and scalable solution to the problem of assessment blockage that eats into already limited resources in education systems worldwide.

Continue Reading

DLVR: Using personalized medicine and nature’s cellular toolkit to target cancer tumours

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. This post coincided with World Cancer Day.

DLVR TherapeuticsWhat if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?

Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver drugs designed to deactivate cancer-promoting genes within the tumour, while minimizing the addition of toxins to the patient’s body.

Personalized medicine research in Toronto also benefited from a recent  $50 million donation to support Princess Margaret Hospital (part of the University Health Network). Read and watch the news announcement on BioTechnology Focus.

This is personalized medicine’s promise for cancer treatment: targeted therapies that stand a better chance of success, with reduced side effects, based on the unique profile of a patient’s tumour, either administered on their own or in combination with traditional chemotherapy.

Continue Reading
Back To Top